# Retlirafusp Alfa Injection Plus Chemotherapy Versus Investigator's Choice of Anti-PD-1 Antibody Plus Chemotherapy as First-line Treatment for Advanced Gastric Cancer With Liver Metastases

> **NCT07677293** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Peking University** · enrollment: 332 (estimated)

## Conditions studied

- Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma

## Interventions

- **DRUG:** Retlirafusp alfa Injection
- **DRUG:** Capecitabine
- **DRUG:** Oxaliplatin
- **DRUG:** Sintilimab or Tislelizumab (based on investigator's choice)
- **DRUG:** Capecitabine
- **DRUG:** Oxaliplatin

## Key facts

- **NCT ID:** NCT07677293
- **Lead sponsor:** Peking University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-26
- **Primary completion:** 2028-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 332 (ESTIMATED)
- **Last updated:** 2026-06-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07677293

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07677293, "Retlirafusp Alfa Injection Plus Chemotherapy Versus Investigator's Choice of Anti-PD-1 Antibody Plus Chemotherapy as First-line Treatment for Advanced Gastric Cancer With Liver Metastases". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07677293. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*